TCWP’s Denali Therapeutics DNLI Stock Holding History

TCWP’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34	Closed	-$1K	–	665
2022 Q1	$1K	Buy	+34	New	+$1.17K	﹤0.01%	1487

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

TCWP's DNLI Position: Q2 2022 in Review

TCWP sold out of Denali Therapeutics (DNLI) in Q2 2022, closing a stake of 34 shares — an estimated $1K sold.

TCWP first reported a position in DNLI in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 188 funds tracked by Wall St. Rank hold DNLI as of Q2 2022.

TCWP reported no remaining Denali Therapeutics position as of Q2 2022 after selling out during the quarter.
TCWP sold 34 Denali Therapeutics shares in Q2 2022, an estimated $1K.
TCWP first reported a position in Denali Therapeutics in Q1 2022 and held it in 1 quarter.
TCWP's Denali Therapeutics position peaked at $1K in Q1 2022.
188 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.